January 30, 2024
January 30, 2024
2022 Genetic and neuropathological studies have strongly implicated microglia in the development and progression of Alzheimer’s disease (AD). Yet precisely how AD risk genes alter microglial function to impact amyloid beta pathology remains unclear. One popular hypothesis is that microglial risk genes reduce amyloid beta clearance from the brain by impairing ...
December 18, 2020
July 6, 2024
January 30, 2024
Recent evidence suggests that molecular markers of Alzheimer’s disease may differ by race, but existing studies have been limited by small sample sizes. The Alzheimer’s Disease Research Centers at Washington University in St. Louis and Emory University have embarked on a collaboration to share spinal fluid and plasma samples from ...
February 18, 2020
January 30, 2024
January 30, 2024
Topline: A safety study published in The New England Journal of Medicine assessed the use of focused ultrasound (FUS) with anti-amyloid immunotherapy aducanumab (marketed as Aduhelm) in three patients with mild cognitive impairment and amyloid pathology. Each person was treated for six months with aducanumab delivered through FUS on just one ...
January 30, 2024
One America Charity Ride 3,200 Mile Update – April 25, 2017 When I last reported, I was just recovering from bruised ribs in Louisville. I am happy to report that I am now feeling much better in Confluence, PA. On the home stretch now. Some of you have asked if there would be a ...
April 27, 2018
A paper published in Neuron by first author Ana Griciuc and Cure Alzheimer’s Fund’s Research Leadership Group members Rudy Tanzi and Marco Colonna has made important headway in answering an open problem in Alzheimer’s research: how do two risk genes for Alzheimer’s disease, CD33 and TREM2, interact to modulate pathology and memory? ...
July 12, 2019